Nicardipine Aguettant

Nicardipine Aguettant



Laboratoire Aguettant


HK Medical Supplies
Health Express
Concise Prescribing Info
Nicardipine HCl
Acute life-threatening HTN, particularly in the event of malignant arterial HTN/hypertensive encephalopathy; aortic dissection, when short-acting β-blocker therapy is not suitable, or in combination w/ a β-blocker when β-blocking alone is not effective; severe pre-eclampsia, when other IV antihypertensive agents are not recommended or are contraindicated. Post-op HTN.
Dosage/Direction for Use
IV Adult Initial dose: Continuous infusion at a rate of 3-5 mg/hr for 15 min; can be increased by increments of 0.5 or 1 mg every 15 min. Max: 15 mg/hr. Maintenance dose: Progressively reduce to 2-4 mg/hr when target pressure is reached. Paed patient Initial dose: 0.5-5 mcg/kg/min. Maintenance dose: 1-4 mcg/kg/min. Elderly, pregnant w/ pre-eclampsia & patient w/ hepatic &/or renal failure Continuous infusion starting at 1-5 mg/hr; can be increased or decreased by increments of 0.5 mg/hr after 30 min. Max: 15 mg/hr.
Hypersensitivity. Severe aortic stenosis. Compensatory HTN, in case of an arteriovenous shunt or aortic coarctation. Unstable angina. W/in 8 days after MI.
Special Precautions
Administer w/ caution to avoid excessive fall in BP. Patients w/ congestive cardiac failure or pulmonary oedema, particularly when receiving concomitant β-blockers; suspected coronary ischaemia; portal HTN; pre-existing intracranial HTN; acute cerebral infarction; patients w/ decreased cardiac function concomitantly using a β-blocker. Concomitant use of Mg sulphate in pregnant women. Infusion site reactions w/ prolonged duration of administration & in peripheral veins. May impair ability to drive or operate machinery. Patients w/ history of hepatic dysfunction or failure. Patients w/ renal failure. Pregnancy. Should not be used during breastfeeding. Elderly ≥65 yr. Infants or childn.
Adverse Reactions
Headache. Dizziness; lower limb oedema, palpitations, hypotension, tachycardia; orthostatic hypotension; nausea, vomiting; flushing.
Drug Interactions
Potentially dangerous to combine w/ dantrolene. Increased adverse effects w/ idelalisib. Elevated plasma levels of cyclosporine, tacrolimus or sirolimus. Decreased plasma conc w/ CYP3A4 inducers (eg, carbamazepine, phenobarb, phenytoin, fosphenytoin, primidone, rifampicin). Increased plasma conc w/ potent CYP3A4 inhibitors (eg, cimetidine, clarithromycin, cobicistat, erythromycin, itraconazole, grapefruit juice, ketoconazole, nelfinavir, posaconazole, ritonavir, telaprevir, telithromycin, voriconazole). Potentiated antihypertensive effect w/ baclofen, urologic α-blockers (alfuzosin, doxazosin, prazosin, silodosin, tamsulosin, terazosin), α-blocking antihypertensive agents (doxazosin, prazosin, urapidil), TCAs (eg, imipramine), neuroleptics, opioids & amifostine. Increased risk of orthostatic hypotension w/ nitrate derivatives or related agents & other orthostatic hypotension-causing medicinal products. Potential additive or synergistic hypotensive effect w/ inhalational anaesthetics. Enhanced negative inotropic effect of β-blockers in cardiac failure (bisoprolol, carvedilol, metoprolol, nebivolol). Possible risk of pulmonary oedema or excessive decrease in BP w/ Mg sulphate. Increased plasma levels of digoxin. Decreased antihypertensive effect w/ IV corticosteroids (glucocorticoids & mineralocorticoids) & tetracosactide (except for hydrocortisone used as replacement therapy in Addison's disease). Reduced dose requirements of vecuronium infusion.
MIMS Class
Calcium Antagonists
ATC Classification
C08CA04 - nicardipine ; Belongs to the class of dihydropyridine derivative selective calcium-channel blockers with mainly vascular effects. Used in the treatment of cardiovascular diseases.
Nicardipine Aguettant soln for inj/infusion 10 mg/10 mL
10 × 1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in